Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (Diluted Average) (2020 - 2025)

Spyre Therapeutics (SYRE) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $64.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 17009.69% year-over-year to $64.1 million, compared with a TTM value of $64.1 million through Dec 2025, up 17009.69%, and an annual FY2025 reading of $64.1 million, up 17009.69% over the prior year.
  • Shares Outstanding (Diluted Average) was $64.1 million for Q4 2025 at Spyre Therapeutics, up from $346045.0 in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $82.2 million in Q2 2022 and bottomed at $16667.0 in Q1 2025.
  • Average Shares Outstanding (Diluted Average) over 5 years is $28.1 million, with a median of $5.4 million recorded in 2023.
  • Peak annual rise in Shares Outstanding (Diluted Average) hit 17009.69% in 2025, while the deepest fall reached 99.95% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $2.6 million in 2021, then grew by 22.56% to $3.2 million in 2022, then soared by 114.0% to $6.9 million in 2023, then crashed by 94.57% to $374387.0 in 2024, then surged by 17009.69% to $64.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SYRE at $64.1 million in Q4 2025, $346045.0 in Q3 2025, and $60.3 million in Q2 2025.